Walaa Obaid: How Warfarin Went From Poison To Medicine
Walaa Obaid, Former Pharmacist at Oman International Hospita, shared a post on LinkedIn:
”A substance originally developed as a deadly rat poison causing fatal internal bleeding… yet prescribed daily to millions of patients as a life-saving treatment!
Warfarin offers one of the most striking examples in pharmaceutical history that ‘the difference between a lethal toxin and a life-saving medicine lies in a precise understanding of human physiology and meticulously controlled dosing.’
First introduced in the 1940s as a potent rodenticide, clinical research later proved that at precisely calibrated doses, it safely inhibits the vitamin K epoxide reductase enzyme (VKORC1) in the liver. By reducing the synthesis of key clotting factors, it transforms from a rodent poison into a vital defense against:
- Stroke in patients with atrial fibrillation (AFib)
- Deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Thromboembolism in patients with mechanical heart valves
Pharmaceutical innovation isn’t always about discovering inherently harmless molecules from day one—it is also about taming dangerous compounds and carefully re-engineering them to guide patients safely away from life-threatening events.
Sources:
1. Journal of Thrombosis and Haemostasis: Historical documentation of Warfarin’s clinical evolution from a rodenticide to a frontline human anticoagulant.
2. U.S. FDA: Official prescribing information and clinical guidelines for Warfarin therapy and target INR monitoring.”
Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series